Nuvectis Pharma (NVCT) Other financing activities (2021 - 2023)

Nuvectis Pharma (NVCT) has 3 years of Other financing activities data on file, last reported at $14000.0 in Q3 2023.

• For the quarter ending Q3 2023, Other financing activities fell 97.5% year-over-year to $14000.0; the trailing twelve-month figure through Dec 2023 stood at $11.2 million (down 34.43% YoY), and the FY2023 full-year result was $11.2 million, down 30.05% from the prior year.
• Other financing activities eased to $14000.0 in Q3 2023, from $10.5 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $16.0 million in Q1 2022 to a low of $14000.0 in Q3 2023.
• A 3-year average of $3.7 million and a median of $630500.0 in 2022 frame the typical range for Other financing activities.
• Peak annual rise in Other financing activities reached 1954.12% in 2023, while the deepest fall reached 97.5% in 2023.
• Tracing NVCT's Other financing activities over 3 years: stood at $136000.0 in 2021, then surged by 311.03% to $559000.0 in 2022, then tumbled by 97.5% to $14000.0 in 2023.
• Business Quant data shows NVCT's Other financing activities at $14000.0 in Q3 2023, $10.5 million in Q2 2023, and $702000.0 in Q1 2023.